Prosecution Insights
Prosecution Insights
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCMILLIAN, KARA RENITA | 2 | 30.6% | +37.9% |
| ROZOF, TIMOTHY R | 1 | 72.6% | +24.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18429719 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | MCMILLIAN, KARA RENITA | 72d overdue |
| 17715401 | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF PHOSPHOMANNOMUTASE 2 DEFICIENCY | MCMILLIAN, KARA RENITA | 67d overdue |
| 17951342 | ALDOSE REDUCTASE INHIBITORS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME, ACUTE LUNG INFLAMMATION/INJURY, CARDIAC INJURY AND ANTI-VIRAL THERAPY | ROZOF, TIMOTHY R | 76d |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18429719 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | MCMILLIAN, KARA RENITA | 1623 | Other | Non-Final OA | 72d overdue | Pending | Feb 01, 2024 |
| 17951342 | ALDOSE REDUCTASE INHIBITORS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME, ACUTE LUNG INFLAMMATION/INJURY, CARDIAC INJURY AND ANTI-VIRAL THERAPY | ROZOF, TIMOTHY R | 1625 | §112 | Non-Final OA | 76d | Pending | Sep 23, 2022 |
| 17715401 | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF PHOSPHOMANNOMUTASE 2 DEFICIENCY | MCMILLIAN, KARA RENITA | 1623 | §103 | Final Rejection | 67d overdue | Pending | Apr 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial